Drug repurposing for cancer therapy
Open accessThe DOI matches its Crossref record; 508 of the 513 references it cites were found in a registry or an index; 127 of the 249 sources its claims cite were checked for support.
Abstract
Comprehensive review of methods and candidate repurposed drugs for cancer therapy.
Overview
CoChat Summary
## TL;DR
This is a narrative review of drug repurposing for cancer therapy, summarizing experimental and computational strategies, hallmark-targeting examples, tumor microenvironment targets, and nanomaterial-based delivery. It argues that repurposed drugs may speed development and reduce cost, but clinical translation remains limited by bioavailability, dosing, toxicity, and regulatory barriers.
## Key findings
- The review organizes drug repurposing around the 14 hallmarks of cancer and the tumor microenvironment (TME), and notes that repurposed drugs may target multiple malignancy features and support combination therapy.
- It states that conventional drug development can take 10–15 years and cost $1–2 billion, whereas repurposing is faster and cheaper because existing drugs already have known safety, dosage, and toxicity profiles.
- The paper highlights several reported quantitative findings from prior studies, including a 45% risk reduction in thyroid cancer among metformin users in Eastern countries, and lower gynecological cancer occurrence with metformin: HR = 0.60 (95% CI: 0.49–0.74), endometrial cancer HR = 0.65 (95% CI: 0.50–0.85), and ovarian cancer HR = 0.47 (95% CI: 0.27–0.82).
- It also cites a phase I clinical trial of leflunomide in refractory multiple myeloma where disease stabilization occurred in 9 of 11 patients.
## Methods
- Design: Narrative review/systematic overview of published work on drug repurposing for cancer therapy, centered on hallmarks of cancer, TME-targeting therapy, and nanomaterial-based delivery.
- Data/sample: The text does not report a primary study sample; instead, it synthesizes examples from preclinical studies, epidemiological analyses, and clinical trials, and mentions use of databases and tables of repurposed-drug candidates.
- Main analysis: The paper categorizes repurposing strategies into experimental approaches (including phenotypic screening and organoid/tumoroid models) and computational approaches (including molecular docking, network analysis, data mining, similarity analysis, machine learning, and transcriptional signature methods).
## Limitations
- The paper explicitly states that many repurposed drugs have not yet translated into clinical application, and that clinical trial evidence is limited for several TME-targeting candidates.
- It notes several practical barriers: bioavailability limits, instability, poor solubility, toxicity, dosing uncertainty, patent/IP issues, regulatory barriers, and limited funding for trials.
- The text also makes evident, but does not present as a formal limitation, that much of the evidence discussed is preclinical and often based on small or ongoing clinical studies rather than large randomized trials.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
99 Valid · 15 Not valid · 82 Not checked · 27 Own results and interpretations
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“Furthermore, TPL has been shown to induce autophagy-mediated caspase-independent cell death in tumor cells.”
§ Drug repurposing for cancer therapy > Drug repurposing: candidates for the therapeutic targeting of hallmarks of cancer > Inducing cell death
What the sources say
- Disputedcites [91] Zhao F Triptolide induces protective autophagy through activation of the CaMKKβ-AMPK signaling pathway in prostate cancer cells Oncotarget 2016 7 5366 5382 10.18632/oncotarget.6783 26734992 PMC4868692 sourceExperimental — accuracy not yet measured
The Results section (‘Triptolide induces cytoprotective autophagy in PCa cells’; page not supplied) concludes that autophagy protects prostate cancer cells from triptolide-induced death: inhibiting autophagy increased both cell death and caspase-3 cleavage. This is contrary to the attributed claim that triptolide-induced autophagy mediates caspase-independent cell death. (LLM, conf=0.90)
Checked by a reasoning model — may be wrong.
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“Celecoxib has been shown to enhance the efficacy of BRAF/MEKi treatments in melanoma through suppression of the NF-κB pathway.”
§ Drug repurposing for cancer therapy > Drug repurposing: candidates for the therapeutic targeting of hallmarks of cancer > Targeting tumor-promoting inflammation
What the sources say
- Disputedcites [183] Vergani E miR-146a-5p impairs melanoma resistance to kinase inhibitors by targeting COX2 and regulating NFkB-mediated inflammatory mediators Cell Commun. Signal 2020 18 156 10.1186/s12964-020-00601-1 32967672 PMC7510138 sourceExperimental — accuracy not yet measured
The Results section (“Targeting COX2 restores melanoma sensitivity to BRAF/MEKi”; page unavailable) supports increased growth inhibition and cytotoxicity with celecoxib plus BRAF/MEKi in melanoma cells. But it reports noncanonical NF-κB activation, not suppression, and attributes the enhanced apoptotic effects to reduced PGE2 production. The Discussion likewise describes activation of NF-κB signaling cascades during celecoxib-induced cell death. (LLM, conf=0.88)
Checked by a reasoning model — may be wrong.
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“Dong and colleagues reported the nuanced relationship between EGCG and the WNT/β-catenin signaling pathway by demonstrating that overexpression of β-catenin could either augment or reduce the anticancer effects of EGCG.147”
§ Drug repurposing for cancer therapy > Drug repurposing: candidates for the therapeutic targeting of hallmarks of cancer > Interfering with replication
What the sources say
- Disputedcites [147] Dong C Epigallocatechin-3-gallate suppresses the growth of human osteosarcoma by inhibiting the Wnt/β-catenin signalling pathway Bioengineered 2022 13 8490 8502 10.1080/21655979.2022.2051805 35348430 PMC9161922 sourceExperimental — accuracy not yet measured
In “EGCG inhibits OS growth by regulating the Wnt/β-catenin pathway” (Figure 4c–f; page not supplied), the paper reports that β-catenin overexpression inhibited EGCG’s antitumour and pro-apoptotic effects. It was β-catenin knockdown, not overexpression, that strengthened those effects. (LLM, conf=0.91)
Checked by a reasoning model — may be wrong.
hedgedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“Another extensive meta-analysis ascertained a notably lower gynecological cancer occurrence in those undergoing metformin treatment compared to alternative therapies (gynecological cancer: HR = 0.60, 95% CI: 0.49–0.74; endometrial cancer: HR = 0.65, 95% CI: 0.50–0.85; ovarian cancer: HR = 0.47, 95% CI: 0.27–0.82).203”
§ Drug repurposing for cancer therapy > Drug repurposing: candidates for the therapeutic targeting of hallmarks of cancer > Locking phenotypic plasticity
What the sources say
- Disputedcites [203] Yao K Zheng H Li T Association between metformin use and the risk, prognosis of gynecologic cancer Front. Oncol. 2022 12 942380 10.3389/fonc.2022.942380 35898873 PMC9309370 sourceExperimental — accuracy not yet measured
The Discussion section on cancer risk (page not provided) reports no significant association between metformin use and the occurrence of gynecological, endometrial, or ovarian cancer in women with diabetes. The cited hazard ratios appear instead in the Discussion section on prognosis, where they describe overall survival among patients with cancer, not cancer occurrence. (LLM, conf=0.90)
Checked by a reasoning model — may be wrong.
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Notably, high-throughput screening using sophisticated models can identify compounds that mitigate disease symptoms without necessitating pre-existing knowledge about the drug-target interactions.29,30”
§ Drug repurposing for cancer therapy > Drug repurposing strategies
What the sources say
- Partly supportedcites [29] Huang H Zhang P Qu XA Sanseau P Yang L Systematic prediction of drug combinations based on clinical side-effects Sci. Rep. 2014 4 7160 10.1038/srep07160 25418113 PMC4241517 sourceExperimental — accuracy not yet measured
The Abstract (page unavailable) describes a computational model that uses clinical side effects to predict drug combinations, rather than requiring drug-target interaction data. But it does not show that the predicted compounds mitigate disease symptoms; the Discussion (page unavailable) says the predictions need experimental testing. The Abstract also distinguishes this approach from high-throughput screening, which it says is impractical for all possible combinations. (LLM, conf=0.86)
- Could not verifycites [30] Kuhn M Campillos M Letunic I Jensen LJ Bork P A side effect resource to capture phenotypic effects of drugs Mol. Syst. Biol. 2010 6 343 10.1038/msb.2009.98 20087340 PMC2824526 sourceExperimental — accuracy not yet measured
The Introduction (page unavailable) discusses databases of cellular phenotypes and the potential of large-scale computational methods; it does not describe screening sophisticated models to find compounds that relieve disease symptoms. Searches for high-throughput screening, symptom mitigation, and drug-target-independent screening found no passage addressing that claim. (LLM, conf=0.73)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
113 more claims · 51 with their cited sources checked
Create a free account to see all 223 claims and to verify the 21 references still open.
- It may state two separate claims as one. 87
- Probably not a substantial claim. 25
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Self-check results appear here once an independent check has confirmed them.
Cited works that were retracted
Works this paper cites that were later retracted, from the retraction notices publishers deposit. Major when the notice came out before this paper was published.
A note, not an issue: for example, a cited work that was retracted only after this paper was published, which its authors could not have known.
In the paper
“134 Ongoing clinical trials are currently examining the ef fi cacy of simvastatin against various cancers, including breast (NCT00807950, NCT05550415), gastric (NCT01099085, NCT03086291), colorectal (NCT01238094), and bladder (NCT02360618) cancer.”
Cited work 10.1038/cddis.2017.46 · retracted 2025-11-27 · notice 10.1038/s41419-025-08275-8 · this paper published 2024-04-19
Citations
Cites
1 retracted
Li, J., Liu, J., Liang, Z., He, F., Yang, L., Li, P., Jiang, Y., Wang, B., Zhou, C., Wang, Y., et al. (2017) · Cell Death & Disease · doi:10.1038/cddis.2017.46 · Cited by 43 · cited 1×
“134 Ongoing clinical trials are currently examining the ef fi cacy of simvastatin against various cancers, including breast (NCT00807950, NCT05550415), gastric (NCT01099085, NCT03086291), colorectal (NCT01238094), and bladder (NCT02360618) cancer.”
BackgroundRetractedHallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590 · cited 3×
“…is activated in response to numerous DNA damage events including germline or somatic defects in DNA repair, 166 oncogene-induced replication stress, 69 fl awed mitotic chromosome segregation, 167 clashes between replication and transcription machinery 168 or even as a consequence of genotoxic…”
BackgroundInfluentialGene Ontology: tool for the unification of biology
Ashburner, M., Ball, C. A., Blake, J. A., Botstein, D., Butler, H., Cherry, J. M., Davis, A. P., Dolinski, K., Dwight, S. S., Eppig, J. T., et al. (2000) · Nature Genetics · doi:10.1038/75556 · Cited by 43,206
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Tissue-based map of the human proteome
Uhlén, M., Fagerberg, L., Hallström, B. M., Lindskog, C., Oksvold, P., Mardinoglu, A., Sivertsson, Å., Kampf, C., Sjöstedt, E., Asplund, A., et al. (2015) · Science · doi:10.1126/science.1260419 · Cited by 15,286
STRING v10: protein–protein interaction networks, integrated over the tree of life
Szklarczyk, D., Franceschini, A., Wyder, S., Forslund, K., Heller, D., Huerta-Cepas, J., Simonovic, M., Roth, A., Santos, A., Tsafou, K. P., et al. (2015) · Nucleic Acids Research · doi:10.1093/nar/gku1003 · Cited by 10,436
The Human Genome Browser at UCSC
Kent, W. J., Sugnet, C. W., Furey, T. S., Roskin, K. M., Pringle, T. H., Zahler, A. M., & Haussler, A. D. (2002) · Genome Research · doi:10.1101/gr.229102 · Cited by 10,400
Hallmarks of Cancer: New Dimensions
Hanahan, D. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-1059 · Cited by 9,887 · cited 2×
“Furthermore, standardization of speci fi c tumoroid culture conditions is essential for enhancing 67,68 Understanding these hallmarks is pivotal for developing effective strategies for cancer prevention, diagnosis, and treatment.”
BackgroundKEGG: new perspectives on genomes, pathways, diseases and drugs
Kanehisa, M., Furumichi, M., Tanabe, M., Sato, Y., & Morishima, K. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkw1092 · Cited by 8,865
DrugBank 5.0: a major update to the DrugBank database for 2018
Wishart, D. S., Feunang, Y. D., Guo, A. C., Lo, E. J., Marcu, A., Grant, J. R., Sajed, T., Johnson, D., Li, C., Sayeeda, Z., et al. (2018) · Nucleic Acids Research · doi:10.1093/nar/gkx1037 · Cited by 8,404
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
Barretina, J., Caponigro, G., Stransky, N., Venkatesan, K., Margolin, A. A., Kim, S., Wilson, C. J., Lehár, J., Kryukov, G. V., Sonkin, D., et al. (2012) · Nature · doi:10.1038/nature11003 · Cited by 7,950
Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis
Hanahan, D., & Folkman, J. (1996) · Cell · doi:10.1016/s0092-8674(00)80108-7 · Cited by 6,885
Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion
Schreiber, R. D., Old, L. J., & Smyth, M. J. (2011) · Science · doi:10.1126/science.1203486 · Cited by 6,474 · cited 1×
“117 In light of these challenges, an increasing number of immunotherapies have been developed and used to treat tumors.”
BackgroundUnderstanding the tumor immune microenvironment (TIME) for effective therapy
Binnewies, M., Roberts, E. W., Kersten, K., Chan, V., Fearon, D. F., Merad, M., Coussens, L. M., Gabrilovich, D. I., Ostrand-Rosenberg, S., Hedrick, C. C., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0014-x · Cited by 6,145 · cited 1×
“344 In this section, we evaluated the anticancer activity of repurposed drugs from multiple perspectives including the TIME, metabolism microenvironment, mechanical microenvironment, hypoxic micro-environment, acidic niche, innervated niche, and microbial microenvironment.”
MethodRevised Estimates for the Number of Human and Bacteria Cells in the Body
Sender, R., Fuchs, S., & Milo, R. (2016) · PLOS Biology · doi:10.1371/journal.pbio.1002533 · Cited by 5,425 · cited 1×
“213,214 Gut microbiota orchestrate a range of vital physiological functions, from nutrient and drug metabolism and vitamin synthesis to immune regulation and preservation of gastrointestinal structure.”
BackgroundSherr, C. J. (1996) · Science · doi:10.1126/science.274.5293.1672 · Cited by 5,379
Lamb, J., Crawford, E. D., Peck, D., Modell, J. W., Blat, I. C., Wrobel, M. J., Lerner, J., Brunet, J.-P., Subramanian, A., Ross, K. N., et al. (2006) · Science · doi:10.1126/science.1132939 · Cited by 5,257
UniProt: a hub for protein information
The UniProt Consortium (2015) · Nucleic Acids Research · doi:10.1093/nar/gku989 · Cited by 5,106
Gut microbiota in human metabolic health and disease
Fan, Y., & Pedersen, O. (2021) · Nature Reviews Microbiology · doi:10.1038/s41579-020-0433-9 · Cited by 4,724 · cited 1×
“217,218 For example, the Fusobacterium adhesin A antigen found in Fusobacterium nucleatum ( F. nucleatum ) has been associated with the promotion of CRC progression via the E-cadherin/WNT-β -catenin signaling pathway.”
BackgroundDrug repurposing: progress, challenges and recommendations
Pushpakom, S., Iorio, F., Eyers, P. A., Escott, K. J., Hopper, S., Wells, A., Doig, A., Guilliams, T., Latimer, J., McNamee, C., et al. (2019) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.168 · Cited by 4,718
Cancer drug resistance: an evolving paradigm
Holohan, C., Van Schaeybroeck, S., Longley, D. B., & Johnston, P. G. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3599 · Cited by 4,681 · cited 1×
“11,12 Therefore, there remains an urgent need to develop novel treatment strategies with high anti-tumor ef fi cacy and minimal side effects.”
BackgroundHelicobacter pylori Infection and the Development of Gastric Cancer
Uemura, N., Okamoto, S., Yamamoto, S., Matsumura, N., Yamaguchi, S., Yamakido, M., Taniyama, K., Sasaki, N., & Schlemper, R. J. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa001999 · Cited by 4,465
Innate and adaptive immune cells in the tumor microenvironment
Gajewski, T. F., Schreiber, H., & Fu, Y.-X. (2013) · Nature Immunology · doi:10.1038/ni.2703 · Cited by 4,148 · cited 1×
“254,255 These cells have been found to suppress the immune system by inhibiting both the traf fi cking and functionality of T cells through direct and indirect mechanisms.”
BackgroundInflammation and cancer: triggers, mechanisms, and consequences
Greten, F. R., & Grivennikov, S. I. (2019) · Immunity · doi:10.1016/j.immuni.2019.06.025 · Cited by 3,806
PLGA-based nanoparticles: An overview of biomedical applications
Danhier, F., Ansorena, E., Silva, J. M., Coco, R., Le Breton, A., & Préat, V. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.01.043 · Cited by 3,806
(1989) · PubMed · Cited by 3,343
The Tumor Microenvironment Innately Modulates Cancer Progression
Hinshaw, D. C., & Shevde, L. A. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-3962 · Cited by 3,270 · cited 1×
“249 With respect to the different hallmarks of the TME, in the current section we will elaborate on the tumor immune microenvironment (TIME), metabolism microenvironment, hypoxic microenvironment, acidic niche, mechanical microenvironment, and innerved niche (Fig.”
BackgroundGoh, K.-I., Cusick, M. E., Valle, D., Childs, B., Vidal, M., & Barabási, A.-L. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0701361104 · Cited by 3,242
Cellular Senescence: Defining a Path Forward
Gorgoulis, V., Adams, P. D., Alimonti, A., Bennett, D. C., Bischof, O., Bishop, C., Campisi, J., Collado, M., Evangelou, K., Ferbeyre, G., et al. (2019) · Cell · doi:10.1016/j.cell.2019.10.005 · Cited by 3,225
Role of the normal gut microbiota
Jandhyala, S. M. (2015) · World Journal of Gastroenterology · doi:10.3748/wjg.v21.i29.8787 · Cited by 3,001 · cited 1×
“215,216 Intriguingly, although many of these microorganisms play benign or even bene fi cial roles, some can also contribute to disease progression, including cancers.”
BackgroundModes of resistance to anti-angiogenic therapy
Bergers, G., & Hanahan, D. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2442 · Cited by 2,953
Influence of tumour micro-environment heterogeneity on therapeutic response
Junttila, M. R., & de Sauvage, F. J. (2013) · Nature · doi:10.1038/nature12626 · Cited by 2,694
Metformin and reduced risk of cancer in diabetic patients
Evans, J. M. M., Donnelly, L. A., Emslie-Smith, A. M., Alessi, D. R., & Morris, A. D. (2005) · BMJ · doi:10.1136/bmj.38415.708634.f7 · Cited by 2,388 · cited 1×
“190,191 196 Recent studies have indicated that metformin might exert direct anticancer effects on a range of tumor cells, including the elusive CSCs, 197,198 thereby highlighting the multifaceted impact of metformin on cancer cells, as well as its potential to reduce phenotypic plasticity.”
BackgroundEffects of substrate stiffness on cell morphology, cytoskeletal structure, and adhesion
Yeung, T., Georges, P. C., Flanagan, L. A., Marg, B., Ortiz, M., Funaki, M., Zahir, N., Ming, W., Weaver, V., & Janmey, P. A. (2005) · Cell Motility and the Cytoskeleton · doi:10.1002/cm.20041 · Cited by 2,325 · cited 1×
“These components play important roles in regulating cell adhesion, 280 morphology, 281 motility, proliferation, differentiation, and migration.”
BackgroundCancer-related inflammation and treatment effectiveness
Diakos, C. I., Charles, K. A., McMillan, D. C., & Clarke, S. J. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70263-3 · Cited by 2,193 · cited 1×
“176,177 Consequently, using repurposed drugs to modulate in fl ammation has emerged as a potent anticancer strategy.”
BackgroundThe Tumour Microenvironment after Radiotherapy: Mechanisms of Resistance and Recurrence
Barker, H. E., Paget, J. T. E., Khan, A. A., & Harrington, K. J. (2015) · Nature Reviews Cancer · doi:10.1038/nrc3958 · Cited by 2,144 · cited 1×
“9 Similarly, although surgical intervention — the primary treatment for solid tumors — signi fi cantly improves patient survival, its success rate depends on the expertise of the surgeon and the availability of screening methods, including hospital imaging equipment.”
Patient-derived organoids model treatment response of metastatic gastrointestinal cancers
Vlachogiannis, G., Hedayat, S., Vatsiou, A., Jamin, Y., Fernández-Mateos, J., Khan, K., Lampis, A., Eason, K., Huntingford, I., Burke, R., et al. (2018) · Science · doi:10.1126/science.aao2774 · Cited by 2,096 · cited 1×
“46 Tumoroids accurately model human primary tumors, positioning them as an invaluable platform for both foundational research and translational medicine.”
BackgroundRole of hypoxia in cancer therapy by regulating the tumor microenvironment
Jing, X., Yang, F., Shao, C., Wei, K., Xie, M., Shen, H., & Shu, Y. (2019) · Molecular Cancer · doi:10.1186/s12943-019-1089-9 · Cited by 2,054 · cited 1×
“294 Hypoxia occurs when there is an imbalance between the oxygen supply and oxygen requirements of cancerous and stromal cells, and often involves a malfunctioning microvascular system.”
BackgroundQuercetin, Inflammation and Immunity
Li, Y., Yao, J., Han, C., Yang, J., Chaudhry, M., Wang, S., Liu, H., & Yin, Y. (2016) · Nutrients · doi:10.3390/nu8030167 · Cited by 1,999
Vitamin C as an Antioxidant: Evaluation of Its Role in Disease Prevention
Padayatty, S. J., Katz, A., Wang, Y., Eck, P., Kwon, O., Lee, J.-H., Chen, S., Corpe, C., Dutta, A., Dutta, S. K., et al. (2003) · Journal of the American College of Nutrition · doi:10.1080/07315724.2003.10719272 · Cited by 1,949 · cited 1×
“297,298 As an antioxidant, ascorbic acid protects against free radicals, and is involved in several vital physiological functions including collagen formation, wound healing, tissue repair, and maintaining the health of bones, cartilage, and teeth.”
BackgroundMacrophages and metabolism in the tumor microenvironment
Vitale, I., Manic, G., Coussens, L. M., Kroemer, G., & Galluzzi, L. (2019) · Cell Metabolism · doi:10.1016/j.cmet.2019.06.001 · Cited by 1,837 · cited 6×
“Cells that support tumor maintenance include endothelial cells (both vascular and lymphatic) and their af fi liated pericytes, CAFs, and a range of immune cells including tumor-in fi ltrating lymphocytes (TILs) such as T cells, B cells, NK cells, TAMs, and mast cells.”
BackgroundInfluentialCancer metabolism: looking forward
Martínez-Reyes, I., & Chandel, N. S. (2021) · Nature Reviews Cancer · doi:10.1038/s41568-021-00378-6 · Cited by 1,824 · cited 1×
“267 More recently, it has become apparent that not only the metabolism of cancer cells but also that of stromal and immune cells within the TME plays a pivotal role in tumor maintenance.”
BackgroundWnt activity defines colon cancer stem cells and is regulated by the microenvironment
Vermeulen, L., De Sousa E Melo, F., van der Heijden, M., Cameron, K., de Jong, J. H., Borovski, T., Tuynman, J. B., Todaro, M., Merz, C., Rodermond, H., et al. (2010) · Nature Cell Biology · doi:10.1038/ncb2048 · Cited by 1,804
Why 90% of clinical drug development fails and how to improve it?
Sun, D., Gao, W., Hu, H., & Zhou, S. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.02.002 · Cited by 1,763 · cited 1×
“15 The strategies of drug repurposing involve exploring new therapeutic applications for drugs that have already been approved.”
BackgroundReactome: a database of reactions, pathways and biological processes
Croft, D., O'Kelly, G., Wu, G., Haw, R., Gillespie, M., Matthews, L., Caudy, M., Garapati, P., Gopinath, G., Jassal, B., et al. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkq1018 · Cited by 1,751
Krtolica, A., Parrinello, S., Lockett, S., Desprez, P.-Y., & Campisi, J. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.211053698 · Cited by 1,730
The RB and p53 pathways in cancer
Sherr, C. J., & McCormick, F. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00102-2 · Cited by 1,690
Schwabe, R. F., & Jobin, C. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3610 · Cited by 1,689
STITCH 5: augmenting protein–chemical interaction networks with tissue and affinity data
Szklarczyk, D., Santos, A., von Mering, C., Jensen, L. J., Bork, P., & Kuhn, M. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkv1277 · Cited by 1,687
Immune evasion in cancer: mechanistic basis and therapeutic strategies
Vinay, D. S., Ryan, E. P., Pawelec, G., Talib, W. H., Stagg, J., Elkord, E., Lichtor, T., Decker, W. K., Whelan, R. L., Kumara, H. M. C. S., et al. (2015) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2015.03.004 · Cited by 1,625
UniRef: comprehensive and non-redundant UniProt reference clusters
Suzek, B. E., Huang, H., McGarvey, P., Mazumder, R., & Wu, C. H. (2007) · Bioinformatics · doi:10.1093/bioinformatics/btm098 · Cited by 1,613
Self-citationNew approaches and procedures for cancer treatment: Current perspectives
Debela, D. T., Muzazu, S. G., Heraro, K. D., Ndalama, M. T., Mesele, B. W., Haile, D. C., Kitui, S. K., & Manyazewal, T. (2021) · SAGE Open Medicine · doi:10.1177/20503121211034366 · Cited by 1,597
The Cancer Stem Cell Niche: How Essential Is the Niche in Regulating Stemness of Tumor Cells?
Plaks, V., Kong, N., & Werb, Z. (2015) · Cell Stem Cell · doi:10.1016/j.stem.2015.02.015 · Cited by 1,557
Calvo, F., Ege, N., Grande-Garcia, A., Hooper, S., Jenkins, R. P., Chaudhry, S. I., Harrington, K., Williamson, P., Moeendarbary, E., Charras, G., et al. (2013) · Nature Cell Biology · doi:10.1038/ncb2756 · Cited by 1,478
Phosphoenolpyruvate Is a Metabolic Checkpoint of Anti-tumor T Cell Responses
Ho, P.-C., Bihuniak, J. D., Macintyre, A. N., Staron, M., Liu, X., Amezquita, R., Tsui, Y.-C., Cui, G., Micevic, G., Perales, J. C., et al. (2015) · Cell · doi:10.1016/j.cell.2015.08.012 · Cited by 1,462 · cited 1×
“271 This concept of “ oncometabolites ” has ushered in a new era for cancer treatment.”
BackgroundMechanobiology of YAP and TAZ in physiology and disease
Panciera, T., Azzolin, L., Cordenonsi, M., & Piccolo, S. (2017) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm.2017.87 · Cited by 1,461 · cited 1×
“282 287 Many studies have focused on the cellular proteins involved in mechanosensing, such as integrins and focal adhesion proteins, and their associated molecular mechanisms including cytoskeleton remodeling, integrin signaling, Rho signaling, and Hippo signaling.”
BackgroundThe SIDER database of drugs and side effects
Kuhn, M., Letunic, I., Jensen, L. J., & Bork, P. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkv1075 · Cited by 1,451
The hallmarks of cancer metabolism: still emerging
Pavlova, N. N., Zhu, J., & Thompson, C. B. (2022) · Cell Metabolism · doi:10.1016/j.cmet.2022.01.007 · Cited by 1,418 · cited 1×
“101 In the past decade, only a few metabolism-based cancer drugs have been successfully developed, some of which are in or nearing clinical trials.”
BackgroundThe Influence of the Gut Microbiome on Cancer, Immunity, and Cancer Immunotherapy
Gopalakrishnan, V., Helmink, B. A., Spencer, C. N., Reuben, A., & Wargo, J. A. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.03.015 · Cited by 1,392
The reverse Warburg effect: Aerobic glycolysis in cancer associated fibroblasts and the tumor stroma
Pavlides, S., Whitaker-Menezes, D., Castello-Cros, R., Flomenberg, N., Witkiewicz, A. K., Frank, P. G., Casimiro, M. C., Wang, C., Fortina, P., Addya, S., et al. (2009) · Cell Cycle · doi:10.4161/cc.8.23.10238 · Cited by 1,391 · cited 1×
“270 Tumor metabolic reprogramming also plays a pivotal role in shaping the immune response, speci fi cally antitumor immunity.”
BackgroundCellular senescence promotes adverse effects of chemotherapy and cancer relapse
Demaria, M., O'Leary, M. N., Chang, J., Shao, L., Liu, S., Alimirah, F., Koenig, K., Le, C., Mitin, N., Deal, A. M., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0241 · Cited by 1,338 · cited 1×
“232 Pioneering research has shown that senescent cells possess the capability to initiate malignancy in benign cells both in culture and in animal models.”
BackgroundThe microbiome and human cancer
Sepich-Poore, G. D., Zitvogel, L., Straussman, R., Hasty, J., Wargo, J. A., & Knight, R. (2021) · Science · doi:10.1126/science.abc4552 · Cited by 1,332 · cited 2×
“214 Emerging evidence has highlighted the intricate relationship between the gut microbiota and conventional anticancer treatments, such as chemotherapy, radiotherapy, targeted therapy, and immunotherapy.”
BackgroundThe updated landscape of tumor microenvironment and drug repurposing
Jin, M.-Z., & Jin, W.-L. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00280-x · Cited by 1,262 · cited 1×
“248 Thus, an accurate and detailed understanding of the TME and other specialized TMEs will be bene fi cial in the development of potential cancer therapies.”
BackgroundSelf-citationThe microbiome, cancer, and cancer therapy
Helmink, B. A., Khan, M. A. W., Hermann, A., Gopalakrishnan, V., & Wargo, J. A. (2019) · Nature Medicine · doi:10.1038/s41591-019-0377-7 · Cited by 1,200 · cited 1×
“335 In contrast, other microbes can promote tumor initiation and progression directly by generating toxic or tumorigenic products or indirectly by shaping a pro-or anti-in fl ammatory microenvironment.”
BackgroundTargeting cancer metabolism in the era of precision oncology
Stine, Z. E., Schug, Z. T., Salvino, J. M., & Dang, C. V. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00339-6 · Cited by 1,189 · cited 1×
“99 In cancer cells, tailored modi fi cation of metabolic fl ux across diverse pathways caters to the heightened energy and synthesis demands intrinsic to tumor proliferation.”
BackgroundTumor-associated macrophages: an accomplice in solid tumor progression
Chen, Y., Song, Y., Du, W., Gong, L., Chang, H., & Zou, Z. (2019) · Journal of Biomedical Science · doi:10.1186/s12929-019-0568-z · Cited by 1,096 · cited 1×
“244,257 Given this highly intricate milieu, a synergistic approach integrating ICIs with therapies that speci fi cally target the TIME such as cytokine therapy, oncolytic viruses, and anti-angiogenic treatments could potentially increase antitumor immune responses.”
BackgroundMechanisms of receptor tyrosine kinase activation in cancer
Du, Z., & Lovly, C. M. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0782-4 · Cited by 1,066 · cited 1×
“70 The phosphatidylinositol 3-kinase/protein kinase B (PI3K/AKT), mammalian target of rapamycin (mTOR), 71 and mitogen-activated protein kinases/ extracellular signal-regulated kinase (MAPK/ERK) pathways have all been implicated in sustaining proliferative signaling.”
BackgroundDiabetes and Cancer: A Consensus Report
Giovannucci, E., Harlan, D. M., Archer, M. C., Bergenstal, R. M., Gapstur, S. M., Habel, L. A., Pollak, M., Regensteiner, J. G., & Yee, D. (2010) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20078 · Cited by 1,055 · cited 1×
“190,191 196 Recent studies have indicated that metformin might exert direct anticancer effects on a range of tumor cells, including the elusive CSCs, 197,198 thereby highlighting the multifaceted impact of metformin on cancer cells, as well as its potential to reduce phenotypic plasticity.”
BackgroundRegulatory T (Treg) cells in cancer: Can Treg cells be a new therapeutic target?
Ohue, Y., & Nishikawa, H. (2019) · Cancer Science · doi:10.1111/cas.14069 · Cited by 1,041
Gold Nanoparticles in Diagnostics and Therapeutics for Human Cancer
Singh, P., Pandit, S., Mokkapati, V. R. S. S., Garg, A., Ravikumar, V., & Mijakovic, I. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19071979 · Cited by 1,038 · cited 1×
“370,371 Their prominence as anticancer therapeutic agents arises from their unparalleled stability, substantial drug-loading capacities, potent targeting capabilities, and precise drug-release mechanisms.”
BackgroundThe molecular mechanisms and therapeutic strategies of EMT in tumor progression and metastasis
Huang, Y., Hong, W., & Wei, X. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01347-8 · Cited by 1,032 · cited 1×
“153,154 Accumulating evidence has indicated that repurposed drugs may have a signi fi cant role in targeting these pivotal signaling pathways, and may, therefore, exhibit potential antitumor effects across diverse metastatic cancer models.”
BackgroundThe BioGRID interaction database: 2013 update
Chatr-aryamontri, A., Breitkreutz, B.-J., Heinicke, S., Boucher, L., Winter, A., Stark, C., Nixon, J., Ramage, L., Kolas, N., O’Donnell, L., et al. (2012) · Nucleic Acids Research · doi:10.1093/nar/gks1158 · Cited by 1,017
Donohoe, D. R., Collins, L. B., Wali, A., Bigler, R., Sun, W., & Bultman, S. J. (2012) · Molecular Cell · doi:10.1016/j.molcel.2012.08.033 · Cited by 993 · cited 1×
“205 Furthermore, mounting evidence has suggested that repurposed drugs that target the TME can produce potent antitumor effects.”
BackgroundPanwar, V., Singh, A., Bhatt, M., Tonk, R. K., Azizov, S., Raza, A. S., Sengupta, S., Kumar, D., & Garg, M. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01608-z · Cited by 967 · cited 1×
“70 The phosphatidylinositol 3-kinase/protein kinase B (PI3K/AKT), mammalian target of rapamycin (mTOR), 71 and mitogen-activated protein kinases/ extracellular signal-regulated kinase (MAPK/ERK) pathways have all been implicated in sustaining proliferative signaling.”
BackgroundOpportunities and challenges in phenotypic drug discovery: an industry perspective
Moffat, J. G., Vincent, F., Lee, J. A., Eder, J., & Prunotto, M. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.111 · Cited by 939
Assessment of the Evolution of Cancer Treatment Therapies
Arruebo, M., Vilaboa, N., Sáez-Gutierrez, B., Lambea, J., Tres, A., Valladares, M., & González-Fernández, Á. (2011) · Cancers · doi:10.3390/cancers3033279 · Cited by 931 · cited 1×
“10 The introduction of chemotherapy was a milestone in cancer treatment.”
BackgroundThe sympathetic nervous system induces a metastatic switch in primary breast cancer
Sloan, E. K., Priceman, S. J., Cox, B. F., Yu, S., Pimentel, M. A., Tangkanangnukul, V., Arevalo, J. M. G., Morizono, K., Karanikolas, B. D. W., Wu, L., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0522 · Cited by 930 · cited 1×
“322 Thus, a deeper understanding of the nerve-rich regions within tumors could be bene fi cial for the development of innovative cancer therapeutic strategies.”
BackgroundMetformin and Cancer Risk in Diabetic Patients: A Systematic Review and Meta-analysis
DeCensi, A., Puntoni, M., Goodwin, P., Cazzaniga, M., Gennari, A., Bonanni, B., & Gandini, S. (2010) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-10-0157 · Cited by 918
A side effect resource to capture phenotypic effects of drugs
Kuhn, M., Campillos, M., Letunic, I., Jensen, L. J., & Bork, P. (2010) · Molecular Systems Biology · doi:10.1038/msb.2009.98 · Cited by 899 · cited 1×
“29,30 Current computational methodologies, such as merging drug effects with clinical disease signatures and model systems that predict disease-modifying effects, are available for the selection of drug candidates suitable for drug repurposing in cancer.”
BackgroundTargeting mutant p53 for efficient cancer therapy
Bykov, V. J. N., Eriksson, S. E., Bianchi, J., & Wiman, K. G. (2018) · Nature Reviews Cancer · doi:10.1038/nrc.2017.109 · Cited by 889 · cited 1×
“128,129 However, some tumors are able to bypass these suppressor genes or deactivate pivotal tumor suppressors.”
BackgroundMicrobiota: a key orchestrator of cancer therapy
Roy, S., & Trinchieri, G. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.13 · Cited by 883
The diverse and complex roles of NF-κB subunits in cancer
Perkins, N. D. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3204 · Cited by 852 · cited 1×
“139,140 hTERT-dependent transcription mediated through these pathways allows tumor cells to have unlimited replication capabilities.”
BackgroundRegulated cell death (RCD) in cancer: key pathways and targeted therapies
Peng, F., Liao, M., Qin, R., Zhu, S., Peng, C., Fu, L., Chen, Y., & Han, B. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01110-y · Cited by 832
Inulin: Properties, health benefits and food applications
Shoaib, M., Shehzad, A., Omar, M., Rakha, A., Raza, H., Sharif, H. R., Shakeel, A., Ansari, A., & Niazi, S. (2016) · Carbohydrate Polymers · doi:10.1016/j.carbpol.2016.04.020 · Cited by 828 · cited 1×
“222 Contemporary research has highlighted the potential ef fi cacy of inulin in oncological interventions, particularly due to its capacity to modulate the polymorphic microbiome of the gut.”
BackgroundNF- B as a Critical Link Between Inflammation and Cancer
Karin, M. (2009) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a000141 · Cited by 816
Patient-derived lung cancer organoids as in vitro cancer models for therapeutic screening
Kim, M., Mun, H., Sung, C. O., Cho, E. J., Jeon, H.-J., Chun, S.-M., Jung, D. J., Shin, T. H., Jeong, G. S., Kim, D. K., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-11867-6 · Cited by 812 · cited 1×
“35 Cisplatin, for example, has been found to be less effective in patient-derived organoids (PDOs) generated from non-small cell lung cancer (NSCLC) tissues than from cell lines, highlighting the ability of patient-derived material to provide important information on potential resistance mechanisms.”
BackgroundAlcohol-abuse drug disulfiram targets cancer via p97 segregase adaptor NPL4
Skrott, Z., Mistrik, M., Andersen, K. K., Friis, S., Majera, D., Gursky, J., Ozdian, T., Bartkova, J., Turi, Z., Moudry, P., et al. (2017) · Nature · doi:10.1038/nature25016 · Cited by 807 · cited 1×
“111 Notably, DSF has recently attracted attention for its potent anticancer effects and its capacity to modulate cellular energy metabolism.”
BackgroundA Randomized, Controlled Trial of Oral Propranolol in Infantile Hemangioma
Léauté-Labrèze, C., Hoeger, P., Mazereeuw-Hautier, J., Guibaud, L., Baselga, E., Posiunas, G., Phillips, R. J., Caceres, H., Lopez Gutierrez, J. C., Ballona, R., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1404710 · Cited by 801
Appreciating force and shape—the rise of mechanotransduction in cell biology
Iskratsch, T., Wolfenson, H., & Sheetz, M. P. (2014) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3903 · Cited by 798 · cited 2×
“281 Consequently, treatments targeting the mechanical TME represent an emerging strategy in targeted therapy.”
BackgroundWang, Y., Zhang, S., Li, F., Zhou, Y., Zhang, Y., Wang, Z., Zhang, R., Zhu, J., Ren, Y., Tan, Y., et al. (2019) · Nucleic Acids Research · doi:10.1093/nar/gkz981 · Cited by 794
The Intestinal Microbiota in Colorectal Cancer.
Tilg, H., Adolph, T. E., Gerner, R. R., & Moschen, A. R. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.03.004 · Cited by 777 · cited 1×
“219 While some micro-organisms affect tumorigenesis directly, others enhance antitumor immune responses, effectively serving as immune adjuvants.”
BackgroundThe microbiome in cancer immunotherapy: Diagnostic tools and therapeutic strategies
Zitvogel, L., Ma, Y., Raoult, D., Kroemer, G., & Gajewski, T. F. (2018) · Science · doi:10.1126/science.aar6918 · Cited by 777
Metabolic reprogramming and epigenetic modifications on the path to cancer
Sun, L., Zhang, H., & Gao, P. (2022) · Protein & Cell · doi:10.1007/s13238-021-00846-7 · Cited by 770
Emodin: A Review of its Pharmacology, Toxicity and Pharmacokinetics
Dong, X., Fu, J., Yin, X., Cao, S., Li, X., Lin, L., Huyiligeqi, & Ni, J. (2016) · Phytotherapy Research · doi:10.1002/ptr.5631 · Cited by 762 · cited 1×
“272,273 More recently, the role of emodin in metabolic reprogramming has become an area of interest, and its role as a promising metabolic inhibitor has expanded its potential applications for cancer treatment.”
BackgroundBenson, D. A., Cavanaugh, M., Clark, K., Karsch-Mizrachi, I., Ostell, J., Pruitt, K. D., & Sayers, E. W. (2018) · Nucleic Acids Research · doi:10.1093/nar/gkx1094 · Cited by 760
Detection and Characterization of Tumor Hypoxia Using pO 2 Histography
Vaupel, P., Höckel, M., & Mayer, A. (2007) · Antioxidants & Redox Signaling · doi:10.1089/ars.2007.1628 · Cited by 728
A Practical Guide to The Cancer Genome Atlas (TCGA)
Wang, Z., Jensen, M. A., & Zenklusen, J. C. (2016) · Methods in Molecular Biology · doi:10.1007/978-1-4939-3578-9_6 · Cited by 723
How Do Cytotoxic Lymphocytes Kill Cancer Cells?
Martínez-Lostao, L., Anel, A., & Pardo, J. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0685 · Cited by 717 · cited 1×
“114 However, during tumor progression, the immunosuppressive mechanisms within the TME become more pronounced.”
BackgroundParhi, L., Alon-Maimon, T., Sol, A., Nejman, D., Shhadeh, A., Fainsod-Levi, T., Yajuk, O., Isaacson, B., Abed, J., Maalouf, N., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-16967-2 · Cited by 716 · cited 1×
“336 In addition, the F. nucleatum DNA load in MSI-high CRC tumors was found to be inversely correlated with the density of tumor-in fi ltrating FOXP3 + T cells, and positively correlated with the ratio of M2-like TAMs to total TAMs, suggesting that F. nucleatum primarily promotes tumor progression…”
ResultBatiha, G. E.-S., Beshbishy, A. M., Ikram, M., Mulla, Z. S., El-Hack, M. E. A., Taha, A. E., Algammal, A. M., & Elewa, Y. H. A. (2020) · Foods · doi:10.3390/foods9030374 · Cited by 709 · cited 2×
“235 Its anti-in fl ammatory and antioxidant properties, as well as its ability to modulate the TME, have led to its inclusion in functional foods as a commercial dietary supplement.”
BackgroundTelomerase modulates Wnt signalling by association with target gene chromatin
Park, J.-I., Venteicher, A. S., Hong, J. Y., Choi, J., Jun, S., Shkreli, M., Chang, W., Meng, Z., Cheung, P., Ji, H., et al. (2009) · Nature · doi:10.1038/nature08137 · Cited by 707 · cited 1×
“The noncanonical roles of hTERT in cancer progression involve the WNT/ β ‐ catenin 137,138 and nuclear factor ‐ κ B (NF-κ B) signaling pathways.”
BackgroundNutrition and cancer: A review of the evidence for an anti-cancer diet
Donaldson, M. S. (2004) · Nutrition Journal · doi:10.1186/1475-2891-3-19 · Cited by 699
Sanz, M. A., Fenaux, P., Tallman, M. S., Estey, E. H., Löwenberg, B., Naoe, T., Lengfelder, E., Döhner, H., Burnett, A. K., Chen, S.-J., et al. (2019) · Blood · doi:10.1182/blood-2019-01-894980 · Cited by 664 · cited 1×
“20 In this review, we embark on a comprehensive examination of drug repurposing as a potential strategy for the treatment of cancer.”
BackgroundCalcinotto, A., Filipazzi, P., Grioni, M., Iero, M., De Milito, A., Ricupito, A., Cova, A., Canese, R., Jachetti, E., Rossetti, M., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-1272 · Cited by 640 · cited 1×
“307 Thus, drug repurposing aimed at neutralizing acidic niches might offer a viable approach to stabilize pH levels within the TME.”
BackgroundReview of Drug Repositioning Approaches and Resources
Xue, H., Li, J., Xie, H., & Wang, Y. (2018) · International Journal of Biological Sciences · doi:10.7150/ijbs.24612 · Cited by 614
Jotte, R., Cappuzzo, F., Vynnychenko, I., Stroyakovskiy, D., Rodríguez-Abreu, D., Hussein, M., Soo, R., Conter, H. J., Kozuki, T., Huang, K.-C., et al. (2020) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2020.03.028 · Cited by 599
Drug repurposing: a promising tool to accelerate the drug discovery process
Parvathaneni, V., Kulkarni, N. S., Muth, A., & Gupta, V. (2019) · Drug Discovery Today · doi:10.1016/j.drudis.2019.06.014 · Cited by 597 · cited 2×
“27,28 More often, these techniques are synergistically utilized.”
BackgroundMethodCancer acidity: An ultimate frontier of tumor immune escape and a novel target of immunomodulation
Huber, V., Camisaschi, C., Berzi, A., Ferro, S., Lugini, L., Triulzi, T., Tuccitto, A., Tagliabue, E., Castelli, C., & Rivoltini, L. (2017) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.03.001 · Cited by 595 · cited 1×
“305 For example, exposure of melanoma cells to extracellular acidosis for 24 hours led to increased expression of EMT markers and enhanced in vitro invasiveness.”
BackgroundFlicek, P., Amode, M. R., Barrell, D., Beal, K., Brent, S., Chen, Y., Clapham, P., Coates, G., Fairley, S., Fitzgerald, S., et al. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkq1064 · Cited by 594
Aloe‐emodin: A review of its pharmacology, toxicity, and pharmacokinetics
Dong, X., Zeng, Y., Liu, Y., You, L., Yin, X., Fu, J., & Ni, J. (2020) · Phytotherapy Research · doi:10.1002/ptr.6532 · Cited by 591
Therapeutic potentials of baicalin and its aglycone, baicalein against inflammatory disorders
Dinda, B., Dinda, S., DasSharma, S., Banik, R., Chakraborty, A., & Dinda, M. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.03.004 · Cited by 541 · cited 1×
“207,208 More recently, a role for BE in non-mutational epigenetic regulation has been described.”
BackgroundNoble Metal Nanoparticles Applications in Cancer
Conde, J., Doria, G., & Baptista, P. (2012) · Journal of Drug Delivery · doi:10.1155/2012/751075 · Cited by 541 · cited 1×
“370,371 Their prominence as anticancer therapeutic agents arises from their unparalleled stability, substantial drug-loading capacities, potent targeting capabilities, and precise drug-release mechanisms.”
BackgroundNF-κB: blending metabolism, immunity, and inflammation
Capece, D., Verzella, D., Flati, I., Arboretto, P., Cornice, J., & Franzoso, G. (2022) · Trends in Immunology · doi:10.1016/j.it.2022.07.004 · Cited by 538
Metformin and Its Benefits for Various Diseases
Lv, Z., & Guo, Y. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.00191 · Cited by 535 · cited 1×
“190,191 196 Recent studies have indicated that metformin might exert direct anticancer effects on a range of tumor cells, including the elusive CSCs, 197,198 thereby highlighting the multifaceted impact of metformin on cancer cells, as well as its potential to reduce phenotypic plasticity.”
BackgroundWnt/β-Catenin Signaling Regulates Telomerase in Stem Cells and Cancer Cells
Hoffmeyer, K., Raggioli, A., Rudloff, S., Anton, R., Hierholzer, A., Del Valle, I., Hein, K., Vogt, R., & Kemler, R. (2012) · Science · doi:10.1126/science.1218370 · Cited by 526 · cited 1×
“The noncanonical roles of hTERT in cancer progression involve the WNT/ β ‐ catenin 137,138 and nuclear factor ‐ κ B (NF-κ B) signaling pathways.”
BackgroundCell motility in cancer invasion and metastasis: insights from simple model organisms
Stuelten, C. H., Parent, C. A., & Montell, D. J. (2018) · Nature Reviews Cancer · doi:10.1038/nrc.2018.15 · Cited by 519 · cited 1×
“153,154 Accumulating evidence has indicated that repurposed drugs may have a signi fi cant role in targeting these pivotal signaling pathways, and may, therefore, exhibit potential antitumor effects across diverse metastatic cancer models.”
BackgroundOvercoming cancer therapeutic bottleneck by drug repurposing
Zhang, Z., Zhou, L., Xie, N., Nice, E. C., Zhang, T., Cui, Y., & Huang, C. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00213-8 · Cited by 516
Phenotypic screening in cancer drug discovery — past, present and future
Moffat, J. G., Rudolph, J., & Bailey, D. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4366 · Cited by 507 · cited 1×
“…experimental approach considers tools such as induced pluripotent stem cell models and function-fi rst phenotypic screenings (or reverse chemical biology), 25,26 while computational methods use target-centric, knowledge-driven, signature-aligned, pathway-focused, and mechanism-speci fi c strategies.”
MethodKupchan, S. M., Court, W. A., Dailey, R. G., Gilmore, C. J., & Bryan, R. F. (1972) · Journal of the American Chemical Society · doi:10.1021/ja00775a078 · Cited by 501 · cited 1×
“84 Since then, its mechanism of action and pharmacological properties have been extensively researched to reveal prominent anti-rheumatic, anti-bacterial, anti-in fl ammatory, and immunomodulatory activities.”
BackgroundLiu, D., & Hornsby, P. J. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-3452 · Cited by 499 · cited 1×
“233,234 Given these insights, the ability of repurposed drugs to act as both inducers of senescence and therapeutic agents targeting senescence has been acknowledged.”
BackgroundMcDonald, O. G., Li, X., Saunders, T., Tryggvadottir, R., Mentch, S. J., Warmoes, M. O., Word, A. E., Carrer, A., Salz, T. H., Natsume, S., et al. (2017) · Nature Genetics · doi:10.1038/ng.3753 · Cited by 494 · cited 1×
“210 Interestingly, the intriguing interactions between BE and HIF-1 α , the glycolytic regulator hexokinase I, and other glycolysis-associated genes suggest a role for BE in controlling the glycolytic pathway and subsequently regulating the energy dynamics of gastrointestinal cancer cells.”
BackgroundSaravia, J., Chapman, N. M., & Chi, H. (2019) · Cellular & Molecular Immunology · doi:10.1038/s41423-019-0220-6 · Cited by 489
Fu, T., Dai, L.-J., Wu, S.-Y., Xiao, Y., Ma, D., Jiang, Y.-Z., & Shao, Z.-M. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01103-4 · Cited by 480
Aguilera, A., & García-Muse, T. (2013) · Annual Review of Genetics · doi:10.1146/annurev-genet-111212-133232 · Cited by 476 · cited 1×
“The DNA damage response (DDR), which is activated in response to numerous DNA damage events including germline or somatic defects in DNA repair, 166 oncogene-induced replication stress, 69 fl awed mitotic chromosome segregation, 167 clashes between replication and transcription machinery 168 or even…”
BackgroundOrganoid Models of Human Liver Cancers Derived from Tumor Needle Biopsies
Nuciforo, S., Fofana, I., Matter, M. S., Blumer, T., Calabrese, D., Boldanova, T., Piscuoglio, S., Wieland, S., Ringnalda, F., Schwank, G., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.07.001 · Cited by 473 · cited 1×
“…stability after hepatic resection and treatment with neoadjuvant combination chemotherapies in colorectal cancer (CRC), 39 as well as gauged drug reactions in hepatocellular carcinoma (HCC) 40,41 and mimicked treatment resistance patterns observed in esophageal squamous cell carcinoma.”
BackgroundApplications of patient-derived tumor xenograft models and tumor organoids
Yoshida, G. J. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0829-z · Cited by 471
Zahalka, A. H., & Frenette, P. S. (2020) · Nature Reviews Cancer · doi:10.1038/s41568-019-0237-2 · Cited by 470 · cited 1×
“319,320 These fi ndings have highlighted novel perspectives on tumor – nerve interactions.”
BackgroundDrug repositioning: a brief overview
Jourdan, J.-P., Bureau, R., Rochais, C., & Dallemagne, P. (2020) · Journal of Pharmacy and Pharmacology · doi:10.1111/jphp.13273 · Cited by 470
Lactic Acid and an Acidic Tumor Microenvironment suppress Anticancer Immunity
Wang, J. X., Choi, S. Y. C., Niu, X., Kang, N., Xue, H., Killam, J., & Wang, Y. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21218363 · Cited by 460
Gandini, S., Puntoni, M., Heckman-Stoddard, B. M., Dunn, B. K., Ford, L., DeCensi, A., & Szabo, E. (2014) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-13-0424 · Cited by 457
Yuan, S., Norgard, R. J., & Stanger, B. Z. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0015 · Cited by 455 · cited 1×
“186 There are three manifestations of phenotypic plasticity: dedifferentiation, blocked differentiation, and transdifferentiation, each representing a distinct disruption to cellular differentiation.”
BackgroundChataway, J., Schuerer, N., Alsanousi, A., Chan, D., MacManus, D., Hunter, K., Anderson, V., Bangham, C. R. M., Clegg, S., Nielsen, C., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(13)62242-4 · Cited by 443
mTOR Kinase Inhibition Causes Feedback-Dependent Biphasic Regulation of AKT Signaling
Rodrik-Outmezguine, V. S., Chandarlapaty, S., Pagano, N. C., Poulikakos, P. I., Scaltriti, M., Moskatel, E., Baselga, J., Guichard, S., & Rosen, N. (2011) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0085 · Cited by 442 · cited 1×
“72,73 In the current landscape of cancer treatment, an increasing number of drugs, originally developed for non-oncological conditions, are being repurposed to target these signaling pathways.”
BackgroundEffect of Proton Pump Inhibitor Pretreatment on Resistance of Solid Tumors to Cytotoxic Drugs
Luciani, F., Spada, M., De Milito, A., Molinari, A., Rivoltini, L., Montinaro, A., Marra, M., Lugini, L., Logozzi, M., Lozupone, F., et al. (2004) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djh305 · Cited by 435 · cited 1×
“310 PPIs have been shown to reduce V-ATPase activity in the acidic niche of cancer cells, thereby disrupting proton transport, and subsequently shifting the pH balance within these cells resulting in increased intracellular concentrations of cytotoxic drugs.”
BackgroundMetformin Therapy and Risk of Cancer in Patients with Type 2 Diabetes: Systematic Review
Franciosi, M., Lucisano, G., Lapice, E., Strippoli, G. F. M., Pellegrini, F., & Nicolucci, A. (2013) · PLoS ONE · doi:10.1371/journal.pone.0071583 · Cited by 428
Statins: a repurposed drug to fight cancer
Jiang, W., Hu, J.-W., He, X.-R., Jin, W.-L., & He, X.-Y. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-02041-2 · Cited by 417
Self-citationJin, G., & Wong, S. T. C. (2014) · Drug Discovery Today · doi:10.1016/j.drudis.2013.11.005 · Cited by 416
Untch, M., Jackisch, C., Schneeweiss, A., Conrad, B., Aktas, B., Denkert, C., Eidtmann, H., Wiebringhaus, H., Kümmel, S., Hilfrich, J., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00542-2 · Cited by 414
Stimuli-responsive polymeric micelles for drug delivery and cancer therapy
Zhou, Q., Zhang, L., Yang, T., & Wu, H. (2018) · International Journal of Nanomedicine · doi:10.2147/ijn.s158696 · Cited by 408
Bhatia, S. N., Chen, X., Dobrovolskaia, M. A., & Lammers, T. (2022) · Nature Reviews Cancer · doi:10.1038/s41568-022-00496-9 · Cited by 406
Immune crosstalk in cancer progression and metastatic spread: a complex conversation
Garner, H., & de Visser, K. E. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-019-0271-z · Cited by 395
Polymeric micelles for oral drug delivery
Gaucher, G., Satturwar, P., Jones, M.-C., Furtos, A., & Leroux, J.-C. (2010) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2010.06.007 · Cited by 389 · cited 1×
“358,359 363 Thus, PMs could act as potential carriers for repurposed drugs.”
BackgroundJarada, T. N., Rokne, J. G., & Alhajj, R. (2020) · Journal of Cheminformatics · doi:10.1186/s13321-020-00450-7 · Cited by 384 · cited 1×
“58 In certain cases, even when a drug has demonstrated promising results, its market entry can be hindered due to con fl icts associated with IP rights.”
BackgroundRecent Advances in Drug Repositioning for the Discovery of New Anticancer Drugs
Shim, J. S., & Liu, J. O. (2014) · International Journal of Biological Sciences · doi:10.7150/ijbs.9224 · Cited by 382 · cited 1×
“23 The inception stage is critical since hypothesis generation is the key to any drug repurposing endeavor.”
BackgroundTelomerase directly regulates NF-κB-dependent transcription
Ghosh, A., Saginc, G., Leow, S. C., Khattar, E., Shin, E. M., Yan, T. D., Wong, M., Zhang, Z., Li, G., Sung, W.-K., et al. (2012) · Nature Cell Biology · doi:10.1038/ncb2621 · Cited by 378 · cited 1×
“139,140 hTERT-dependent transcription mediated through these pathways allows tumor cells to have unlimited replication capabilities.”
BackgroundTriptolide: Progress on research in pharmacodynamics and toxicology
Li, X.-J., Jiang, Z.-Z., & Zhang, L.-Y. (2014) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2014.06.006 · Cited by 378
Computational Drug Repositioning: From Data to Therapeutics
Hurle, M. R., Yang, L., Xie, Q., Rajpal, D. K., Sanseau, P., & Agarwal, P. (2013) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2013.1 · Cited by 373
Cooperative tumorigenic effects of germline mutations in Rb and p53
Williams, B. O., Remington, L., Albert, D. M., Mukai, S., Bronson, R. T., & Jacks, T. (1994) · Nature Genetics · doi:10.1038/ng0894-480 · Cited by 368 · cited 1×
“127 Speci fi - cally, P53 acts as a sentinel, responding to intracellular disturbances like metabolic and oxidative stress, and inducing cell cycle arrest until the TME returns to a balanced state.”
BackgroundCardiovascular actions and therapeutic potential of tanshinone IIA
Gao, S., Liu, Z., Li, H., Little, P. J., Liu, P., & Xu, S. (2012) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2011.06.041 · Cited by 359
Divergent Routes toward Wnt and R-spondin Niche Independency during Human Gastric Carcinogenesis
Nanki, K., Toshimitsu, K., Takano, A., Fujii, M., Shimokawa, M., Ohta, Y., Matano, M., Seino, T., Nishikori, S., Ishikawa, K., et al. (2018) · Cell · doi:10.1016/j.cell.2018.07.027 · Cited by 332 · cited 1×
“37,38 Such models have adeptly mirrored the feasibility of tumoroids in the accurate recapitulation of KRAS-mutant metastatic rectal cancer with microsatellite stability after hepatic resection and treatment with neoadjuvant combination chemotherapies in colorectal cancer (CRC), 39 as well as…”
MethodA review of network-based approaches to drug repositioning
Lotfi Shahreza, M., Ghadiri, N., Mousavi, S. R., Varshosaz, J., & Green, J. R. (2018) · Briefings in Bioinformatics · doi:10.1093/bib/bbx017 · Cited by 330
Tumor microenvironment in gastric cancers
Oya, Y., Hayakawa, Y., & Koike, K. (2020) · Cancer Science · doi:10.1111/cas.14521 · Cited by 328 · cited 1×
“246,247 The TME supports the survival and migration of cancer cells throughout the organism in response to internal or external stimuli, including treatments.”
BackgroundTargeting mitochondrial metabolism for precision medicine in cancer
Sainero-Alcolado, L., Liaño-Pons, J., Ruiz-Pérez, M. V., & Arsenian-Henriksson, M. (2022) · Cell Death & Differentiation · doi:10.1038/s41418-022-01022-y · Cited by 322 · cited 1×
“97 Deregulating cellular energetics has recently been added as a new hallmark of cancer.”
BackgroundAhronian, L. G., Sennott, E. M., Van Allen, E. M., Wagle, N., Kwak, E. L., Faris, J. E., Godfrey, J. T., Nishimura, K., Lynch, K. D., Mermel, C. H., et al. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-1518 · Cited by 322 · cited 1×
“72,73 In the current landscape of cancer treatment, an increasing number of drugs, originally developed for non-oncological conditions, are being repurposed to target these signaling pathways.”
BackgroundQiu, D., & Kao, P. N. (2003) · Drugs in R & D · doi:10.2165/00126839-200304010-00001 · Cited by 311
Stress-Modulated Growth, Residual Stress, and Vascular Heterogeneity
Taber, L. A., & Humphrey, J. D. (2001) · Journal of Biomechanical Engineering · doi:10.1115/1.1412451 · Cited by 309 · cited 1×
“278,279 The formation of a mechanical microenvironment primarily depends on collagen and fi brin, integrins and fi broblasts.”
BackgroundPeng, W., Qin, R., Li, X., & Zhou, H. (2013) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2013.05.007 · Cited by 308 · cited 1×
“272,273 More recently, the role of emodin in metabolic reprogramming has become an area of interest, and its role as a promising metabolic inhibitor has expanded its potential applications for cancer treatment.”
BackgroundA standard database for drug repositioning
Brown, A. S., & Patel, C. J. (2017) · Scientific Data · doi:10.1038/sdata.2017.29 · Cited by 305
Yang, J., Liao, D., Chen, C., Liu, Y., Chuang, T.-H., Xiang, R., Markowitz, D., Reisfeld, R. A., & Luo, Y. (2013) · Stem Cells · doi:10.1002/stem.1281 · Cited by 301 · cited 1×
“124 Thus, OA may be a potential therapeutic agent for the treatment of cancer.”
BackgroundThe role of dendritic cells in cancer and anti-tumor immunity
Marciscano, A. E., & Anandasabapathy, N. (2021) · Seminars in Immunology · doi:10.1016/j.smim.2021.101481 · Cited by 298
Han, K., Nam, J., Xu, J., Sun, X., Huang, X., Animasahun, O., Achreja, A., Jeon, J. H., Pursley, B., Kamada, N., et al. (2021) · Nature Biomedical Engineering · doi:10.1038/s41551-021-00749-2 · Cited by 287 · cited 1×
“224 Moreover, inulin has shown a pronounced ability to inhibit tumor proliferation and extend the latency phase of oncogenesis.”
BackgroundTumor organoids: applications in cancer modeling and potentials in precision medicine
Xu, H., Jiao, D., Liu, A., & Wu, K. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01278-4 · Cited by 286 · cited 1×
“34 The use of tumoroids is expanding, and their utility for basic research and early steps of drug development has been recognized.”
BackgroundGuglin, M., Krischer, J., Tamura, R., Fink, A., Bello-Matricaria, L., McCaskill-Stevens, W., & Munster, P. N. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.03.495 · Cited by 281
Machine and deep learning approaches for cancer drug repurposing
Issa, N. T., Stathias, V., Schürer, S., & Dakshanamurthy, S. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.12.011 · Cited by 274
Nerve–Cancer Cell Cross-talk: A Novel Promoter of Tumor Progression
Jobling, P., Pundavela, J., Oliveira, S. M. R., Roselli, S., Walker, M. M., & Hondermarck, H. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-3180 · Cited by 272 · cited 1×
“319,320 These fi ndings have highlighted novel perspectives on tumor – nerve interactions.”
BackgroundFu, Y.-S., Chen, T.-H., Weng, L., Huang, L., Lai, D., & Weng, C.-F. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.111888 · Cited by 271 · cited 1×
“288,289 Interestingly, curcumin has displayed antitumor properties both in vitro and in vivo, and has been shown to act through multiple cellular pathways.”
BackgroundLiposome and immune system interplay: Challenges and potentials
Zahednezhad, F., Saadat, M., Valizadeh, H., Zakeri-Milani, P., & Baradaran, B. (2019) · Journal of Controlled Release · doi:10.1016/j.jconrel.2019.05.030 · Cited by 267 · cited 1×
“364 Their inherent ability to transport both hydrophobic and hydrophilic agents, 347 combined with their ease of synthesis, extensive surface area, and adaptability for targeted modi fi cations, positions them as a pivotal vehicle for drug delivery.”
BackgroundChronic stress promotes gastric cancer progression and metastasis: an essential role for ADRB2
Zhang, X., Zhang, Y., He, Z., Yin, K., Li, B., Zhang, L., & Xu, Z. (2019) · Cell Death & Disease · doi:10.1038/s41419-019-2030-2 · Cited by 261 · cited 1×
“321 Furthermore, Sloan et al. found that both stress-induced and pharmacological β -adrenergic stimulation promoted macrophage migration into tumor tissue in a mouse model of breast cancer.”
BackgroundRuiz-Núñez, B., Pruimboom, L., Dijck-Brouwer, D. A. J., & Muskiet, F. A. J. (2013) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2013.02.009 · Cited by 246
Goodwin, P. J., Chen, B. E., Gelmon, K. A., Whelan, T. J., Ennis, M., Lemieux, J., Ligibel, J. A., Hershman, D. L., Mayer, I. A., Hobday, T. J., et al. (2022) · JAMA · doi:10.1001/jama.2022.6147 · Cited by 240
Schott, A. F., Goldstein, L. J., Cristofanilli, M., Ruffini, P. A., McCanna, S., Reuben, J. M., Perez, R. P., Kato, G., & Wicha, M. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2748 · Cited by 238
Network-Based Methods for Prediction of Drug-Target Interactions
Wu, Z., Li, W., Liu, G., & Tang, Y. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01134 · Cited by 237
Overcoming the legal and regulatory barriers to drug repurposing
Breckenridge, A., & Jacob, R. (2019) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.92 · Cited by 227 · cited 1×
“374,375 It is our hope that such barriers can be overcome to fully realize the potential of drug repurposing.”
BackgroundZheng, T., Yang, X., Wu, D., Xing, S., Bian, F., Li, W., Chi, J., Bai, X., Wu, G., Chen, X., et al. (2015) · British Journal of Pharmacology · doi:10.1111/bph.13120 · Cited by 221
Intestinal microbiota in early life and its implications on childhood health
Zhuang, L., Chen, H., Zhang, S., Zhuang, J., Li, Q., & Feng, Z. (2019) · Genomics, Proteomics & Bioinformatics · doi:10.1016/j.gpb.2018.10.002 · Cited by 219 · cited 1×
“217,218 For example, the Fusobacterium adhesin A antigen found in Fusobacterium nucleatum ( F. nucleatum ) has been associated with the promotion of CRC progression via the E-cadherin/WNT-β -catenin signaling pathway.”
BackgroundMueller, N. T., Differding, M. K., Zhang, M., Maruthur, N. M., Juraschek, S. P., Miller, E. R., Appel, L. J., & Yeh, H.-C. (2021) · Diabetes Care · doi:10.2337/dc20-2257 · Cited by 215
Elinav, E., Garrett, W. S., Trinchieri, G., & Wargo, J. (2019) · Nature Reviews Cancer · doi:10.1038/s41568-019-0155-3 · Cited by 215
Cai, J., Yi, M., Tan, Y., Li, X., Li, G., Zeng, Z., Xiong, W., & Xiang, B. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-01995-7 · Cited by 215 · cited 1×
“89 In addition to pyroptosis, Wang and colleagues also found that the use of TPL-loaded polyethylene glycol (PEG) nanocarriers induced necrosis and enhanced the sensitivity of MIA PaCa-2 (pancreatic ductal adenocarcinoma) tumors to gemcitabine.”
BackgroundTumor microenvironment and angiogenesis
Nyberg, P. (2008) · Frontiers in Bioscience · doi:10.2741/3173 · Cited by 212 · cited 1×
“268,269 Endothelial cells are among the most studied stromal cells within the TME.”
BackgroundTargeting telomeres: advances in telomere maintenance mechanism-specific cancer therapies
Gao, J., & Pickett, H. A. (2022) · Nature Reviews Cancer · doi:10.1038/s41568-022-00490-1 · Cited by 212 · cited 1×
“135,136 In addition, human telomerase reverse transcriptase (hTERT) plays an integral role in cancer signaling pathways as a transcriptional regulator, orchestrating the activation of crucial genes that are vital for tumor proliferation and survival.”
BackgroundHOXA5 Counteracts Stem Cell Traits by Inhibiting Wnt Signaling in Colorectal Cancer
Ordóñez-Morán, P., Dafflon, C., Imajo, M., Nishida, E., & Huelsken, J. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.11.001 · Cited by 209 · cited 1×
“189 Exploiting these mechanisms through drug repurposing might offer novel groundbreaking therapeutic approaches.”
BackgroundKunzmann, V., Siveke, J. T., Algül, H., Goekkurt, E., Siegler, G., Martens, U., Waldschmidt, D., Pelzer, U., Fuchs, M., Kullmann, F., et al. (2021) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(20)30330-7 · Cited by 209
5-Fluorouracil treatment induces characteristic T>G mutations in human cancer
(2019) · doi:10.1038/s41467-019-12594-8 · Cited by 201 · cited 1×
“…including germline or somatic defects in DNA repair, 166 oncogene-induced replication stress, 69 fl awed mitotic chromosome segregation, 167 clashes between replication and transcription machinery 168 or even as a consequence of genotoxic anticancer treatments, 169 is a crucial hallmark of cancer.”
BackgroundGęgotek, A., & Skrzydlewska, E. (2022) · Vitamins and hormones · doi:10.1016/bs.vh.2022.10.008 · Cited by 200
Phase II clinical trial of metformin as a cancer stem cell-targeting agent in ovarian cancer
Brown, J. R., Chan, D. K., Shank, J. J., Griffith, K. A., Fan, H., Szulawski, R., Yang, K., Reynolds, R. K., Johnston, C., McLean, K., et al. (2020) · JCI Insight · doi:10.1172/jci.insight.133247 · Cited by 198
Brown, K. K., Spinelli, J. B., Asara, J. M., & Toker, A. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0611 · Cited by 198 · cited 1×
“105,106 In addition, Yamaguchi and colleagues proposed that le fl unomide-mediated pyrimidine synthesis could be a therapeutic target for mitigating the metastatic progression of CRC.”
BackgroundChen, G., Xu, S., Renko, K., & Derwahl, M. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-1754 · Cited by 196 · cited 1×
“190,191 196 Recent studies have indicated that metformin might exert direct anticancer effects on a range of tumor cells, including the elusive CSCs, 197,198 thereby highlighting the multifaceted impact of metformin on cancer cells, as well as its potential to reduce phenotypic plasticity.”
BackgroundOrganoid models of gastrointestinal cancers in basic and translational research
Lau, H. C. H., Kranenburg, O., Xiao, H., & Yu, J. (2020) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-019-0255-2 · Cited by 194
Wang, M., Jiang, S., Zhou, L., Yu, F., Ding, H., Li, P., Zhou, M., & Wang, K. (2019) · International Journal of Biological Sciences · doi:10.7150/ijbs.33710 · Cited by 191 · cited 1×
“290 Of note, curcumin has recently been found to exert antitumor effects by targeting the mechanical microenvironment.”
BackgroundEffects of Beta-Blocker Withdrawal in Acute Decompensated Heart Failure
Prins, K. W., Neill, J. M., Tyler, J. O., Eckman, P. M., & Duval, S. (2015) · JACC: Heart Failure · doi:10.1016/j.jchf.2015.03.008 · Cited by 190
Mechanisms of T-Cell Immunosuppression by Mesenchymal Stromal Cells: What Do We Know So Far?
Haddad, R., & Saldanha-Araujo, F. (2014) · BioMed Research International · doi:10.1155/2014/216806 · Cited by 188 · cited 1×
“256 Moreover, other components of the TIME, such as TAMs, monocytes, and granulocytes, have also been reported to inhibit the antitumor activity of T cells and NK cells via various mechanisms, thereby leading to resistance to immunotherapy.”
BackgroundJacquemet, G., Baghirov, H., Georgiadou, M., Sihto, H., Peuhu, E., Cettour-Janet, P., He, T., Perälä, M., Kronqvist, P., Joensuu, H., et al. (2016) · Nature Communications · doi:10.1038/ncomms13297 · Cited by 186
The combination of disulfiram and copper for cancer treatment
Li, H., Wang, J., Wu, C., Wang, L., Chen, Z.-S., & Cui, W. (2020) · Drug Discovery Today · doi:10.1016/j.drudis.2020.04.003 · Cited by 185 · cited 1×
“109 The anticancer properties of DSF were serendipitously discovered in 1977 when Lewison reported the drug ’ s potential to inhibit bone metastasis in breast cancer patients.”
BackgroundDinda, B., SilSarma, I., Dinda, M., & Rudrapaul, P. (2015) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2014.12.027 · Cited by 182 · cited 1×
“206 Baicalein (BE), a prominent fl avonoid derived from the roots of O. indicum , possesses anti-oxidant, anti-in fl ammatory, anti-hepatotoxic, anti-viral, and antitumor properties.”
BackgroundPhytochemicals targeting NF-κB signaling: Potential anti-cancer interventions
Chauhan, A., Islam, A., Prakash, H., & Singh, S. K. (2021) · Journal of Pharmaceutical Analysis · doi:10.1016/j.jpha.2021.07.002 · Cited by 181 · cited 1×
“179 182 Celecoxib has been shown to enhance the ef fi cacy of BRAF/MEKi treatments in melanoma through suppression of the NF-κ B pathway.”
BackgroundXu, L., Zhang, Y., Tian, K., Chen, X., Zhang, R., Mu, X., Wu, Y., Wang, D., Wang, S., Liu, F., et al. (2018) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-018-0929-6 · Cited by 177 · cited 1×
“259,260 These fi ndings highlight the intertwined relationship between T cell activation, apigenin-dependent PD-L1 regulation, and subsequent cancer cell demise.”
BackgroundSoy Isoflavone Supplementation for Breast Cancer Risk Reduction: A Randomized Phase II Trial
Khan, S. A., Chatterton, R. T., Michel, N., Bryk, M., Lee, O., Ivancic, D., Heinz, R., Zalles, C. M., Helenowski, I. B., Jovanovic, B. D., et al. (2012) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-11-0251 · Cited by 175
Moldogazieva, N. T., Lutsenko, S. V., & Terentiev, A. A. (2018) · Cancer Research · doi:10.1158/0008-5472.can-18-0980 · Cited by 173
Repurposing of drugs: An attractive pharmacological strategy for cancer therapeutics
Kirtonia, A., Gala, K., Fernandes, S. G., Pandya, G., Pandey, A. K., Sethi, G., Khattar, E., & Garg, M. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.04.006 · Cited by 172 · cited 1×
“16 Drug repurposing has several inherent advantages including a faster and more cost-ef fi cient drug development time due to prior knowledge about the safety, dosage, and toxicity pro fi les of existing medications.”
BackgroundBasu, A. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.107943 · Cited by 171 · cited 1×
“228 As such, the initiation of cellular senescence can pose a barrier to tumor development, presenting itself as a potentially favorable outcome for anticancer therapies.”
Background
Cited by
Glaviano, A., Lau, H., Carter, L. M., Lee, E. H. C., Lam, H. Y., Okina, E., Tan, D. J. J., Tan, W., Ang, H. L., Carbone, D., et al. (2025) · Journal of Hematology & Oncology · doi:10.1186/s13045-024-01634-6 · Cited by 183
Applications of Artificial Intelligence in Drug Repurposing
Wan, Z., Sun, X., Li, Y., Chu, T., Hao, X., Cao, Y., & Zhang, P. (2025) · Advanced Science · doi:10.1002/advs.202411325 · Cited by 126
A review of the current trends in computational approaches in drug design and metabolism
Ouma, R. B. O., Ngari, S. M., & Kibet, J. K. (2024) · Discover Public Health · doi:10.1186/s12982-024-00229-3 · Cited by 95
“Similarly, bufulfone and chlorambucil which were initially developed as alkylating agents based on toxic chemical warfare agent mustard gas, have been repurposed for treating leukemia [55].”
Artificial Intelligence in Head and Neck Cancer: Innovations, Applications, and Future Directions
Pham, T. D., Teh, M., Chatzopoulou, D., Holmes, S., & Coulthard, P. (2024) · Current Oncology · doi:10.3390/curroncol31090389 · Cited by 88
“For instance, drugs initially developed for other cancers or diseases may exhibit potential efficacy against HNC, offering a faster and more cost-effective route to developing new treatments [156,157].”
BackgroundAn Open Access Database of Licensed Cancer Drugs
Pantziarka, P., Capistrano, R., Potter, A. D., Vandeborne, L., & Bouche, G. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.627574 · Cited by 70
Metadata
- Authors
- Xia, Y., Sun, M., Huang, H., & Jin, W.-L.
- Affiliations
- Johns Hopkins University (US)
- Guiyang Medical University (CN)
- Corresponding author
- Huang, Hai
- Venue
- Signal Transduction and Targeted Therapy
- Published
- 2024-04-19
- Volume
- 9
- Issue
- 1
- Pages
- 92-92
- ISSN
- 2059-3635 (ISSN-L)
- PMC
- PMC11026526
- OpenAlex
- W4394934376
- Cited by
- 443
- References
- 513
- Citations by year
- 2026: 168 · 2025: 214 · 2024: 60
- FWCI
- 12.35
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Signal Transduction and Targeted Therapy (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- National Natural Science Foundation of China (82060442)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Mechanisms and Therapy
- Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
- Keywords
- drug repurposing, cancer therapy, cancer hallmarks, tumor microenvironment, drug resistance, combination therapy, nanotechnology, topical drug delivery, anticancer agents, clinical translation
- MeSH terms
- Combined Modality Therapy, Humans, Neoplasms, Drug Delivery Systems, Treatment Outcome, Drug Repositioning, Tumor Microenvironment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.